JPH-034 is under clinical development by J-Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JPH-034’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JPH-034 overview

JPH-034 is under development for the treatment of solid tumors, progressive multiple sclerosis and brain tumor. It is administered by oral route. The drug candidate acts by targeting L type amino acid transporter 1 (LAT1).

It was also under development for the treatment of colon cancer and pancreatic cancer.

J-Pharma overview

J-Pharma is a pharmaceutical company that develops original inhibitors of L-type amino acid transporter 1 (LAT1) for the treatment of advanced cancer. The company’s products portfolio includes namburrat, OKY-034, LAT1 inhibitor, NKO-028 and 035. It offers drugs for various cancers which include biliary tract cancer, pancreatic cancer, solid cancer and autoimmune disease in the form intravenous injection and oral administration. The company also carries out different phases of clinical trials. J-Pharma is headquartered in Yokohama, Kanagawa, Japan.

For a complete picture of JPH-034’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.